Literature DB >> 24998706

High-dose reirradiation with intensity-modulated radiotherapy for recurrent head-and-neck cancer: disease control, survival and toxicity.

Fréderic Duprez1, Dieter Berwouts2, Indira Madani2, Katrien Bonte3, Tom Boterberg2, Werner De Gersem2, Philippe Deron3, Wouter Huvenne3, Wilfried De Neve2.   

Abstract

PURPOSE: To evaluate disease control, survival and severe late toxicity after high-dose fractionated reirradiation using intensity-modulated radiotherapy (IMRT) for recurrent head-and-neck cancer.
MATERIALS AND METHODS: Sixty consecutive patients were reirradiated with IMRT between 1997 and 2011. The median prescribed dose was 70 Gy in 35 daily fractions until 2004 and 69.12 Gy in 32 daily fractions thereafter. The median cumulative dose was 132 Gy. Sixty-seven percent of patients had non-metastatic stage IV disease. Surgery prior to reirradiation and concomitant systemic therapy was performed in 13 (22%) and 20 (33%) patients, respectively.
RESULTS: Median follow-up in living patients was 18.5 months. Actuarial 1-, 2- and 5-year locoregional control was 64%, 48% and 32%, respectively. Median overall (OS) and disease-free survival was 9.6 and 6.7 months, respectively. Actuarial 1-, 2- and 5-year OS was 44%, 32% and 22%, respectively. Seventeen (27%) and 2 (3%) patients had grade 3 and 4 acute toxicity, respectively. Cumulative incidence of late grade≥3 toxicity was 23%, 27% and 66% at 1, 2 and 5 years, respectively. In 4 patients, death was attributed to toxicity: fatal bleeding (n=2), aspiration pneumonia (n=1) and skin necrosis (n=1).
CONCLUSIONS: High-dose fractionated reirradiation with IMRT offers 5-year disease control and OS in recurrent head-and-neck cancer for 1/3 and 1/4 patients, respectively. Severe late toxicity after 1-2 and 5 years occurs in 1/4 and 2/3 patients, respectively.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Head-and-neck cancer; IMRT; Radiotherapy; Reirradiation; Toxicity

Mesh:

Year:  2014        PMID: 24998706     DOI: 10.1016/j.radonc.2014.04.018

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  18 in total

Review 1.  Reirradiation of Skull Base Tumors With Advanced Highly Conformal Techniques.

Authors:  Jennifer C Ho; Jack Phan
Journal:  Curr Oncol Rep       Date:  2017-10-28       Impact factor: 5.075

2.  Reirradiation with IMRT for recurrent head and neck cancer: A single-institutional report on disease control, survival, and toxicity.

Authors:  Parveen Ahlawat; Sheh Rawat; Anjali Kakria; Bharti Devnani; Inderjit Kaur Wahi; David K Simson
Journal:  Rep Pract Oncol Radiother       Date:  2017-06-07

3.  Effectiveness and toxicity of helical tomotherapy for patients with locally recurrent nasopharyngeal carcinoma.

Authors:  F Puebla; J L Lopez Guerra; J M Garcia Ramirez; R Matute; I Marrone; C Miguez; D Sevillano; A Sanchez-Reyes; E Rivin Del Campo; J M Praena-Fernandez; I Azinovic
Journal:  Clin Transl Oncol       Date:  2015-06-25       Impact factor: 3.405

4.  A feasibility study on adaptive 18F-FDG-PET-guided radiotherapy for recurrent and second primary head and neck cancer in the previously irradiated territory.

Authors:  Julie Schatteman; Dirk Van Gestel; Dieter Berwouts; Werner De Gersem; Geert De Kerf; Wilfried De Neve; Bie De Ost; Ana Maria Luiza Olteanu; Sylvie Rottey; Tom Vercauteren; Ingeborg Goethals; Fréderic Duprez
Journal:  Strahlenther Onkol       Date:  2018-03-19       Impact factor: 3.621

5.  The development and verification of a highly accurate collision prediction model for automated noncoplanar plan delivery.

Authors:  Victoria Y Yu; Angelia Tran; Dan Nguyen; Minsong Cao; Dan Ruan; Daniel A Low; Ke Sheng
Journal:  Med Phys       Date:  2015-11       Impact factor: 4.071

6.  Volume, Dose, and Fractionation Considerations for IMRT-based Reirradiation in Head and Neck Cancer: A Multi-institution Analysis.

Authors:  Jimmy J Caudell; Matthew C Ward; Nadeem Riaz; Sara J Zakem; Musaddiq J Awan; Neal E Dunlap; Derek Isrow; Comron Hassanzadeh; John A Vargo; Dwight E Heron; Samuel Marcrom; Drexell H Boggs; Chandana A Reddy; Joshua Dault; James A Bonner; Kristin A Higgins; Jonathan J Beitler; Shlomo A Koyfman; Mitchell Machtay; Min Yao; Andy M Trotti; Farzan Siddiqui; Nancy Y Lee
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-12-01       Impact factor: 7.038

7.  Highly conformal reirradiation in patients with prior oropharyngeal radiation: Clinical efficacy and toxicity outcomes.

Authors:  Alexander F Bagley; Adam S Garden; Jay P Reddy; Amy C Moreno; Steven J Frank; David I Rosenthal; William H Morrison; Gary Brandon Gunn; Clifton D Fuller; Shalin J Shah; Renata Ferrarotto; Erich M Sturgis; Neil D Gross; Jack Phan
Journal:  Head Neck       Date:  2020-08-09       Impact factor: 3.147

8.  Predictive value of skin invasion in recurrent head and neck cancer patients treated by hypofractionated stereotactic re-irradiation using a cyberknife.

Authors:  Hideya Yamazaki; Mikio Ogita; Kengo Himei; Satoaki Nakamura; Gen Suzuki; Tadayuki Kotsuma; Ken Yoshida; Yasuo Yoshioka
Journal:  Radiat Oncol       Date:  2015-10-15       Impact factor: 3.481

9.  Proton Radiotherapy for Recurrent or Metastatic Head and Neck Cancers with Palliative Quad Shot.

Authors:  Jennifer Ma; Benjamin H Lok; Jingfeng Zong; Stanley I Gutiontov; Xin Cai; Andrew C Bell; Marina Shcherba; Han Xiao; Eric J Sherman; Chiaojung Jillian Tsai; Nadeem Riaz; Sean M McBride; Oren Cahlon; Nancy Y Lee
Journal:  Int J Part Ther       Date:  2018

Review 10.  Follow-up in Head and Neck Cancer: Do More Does It Mean Do Better? A Systematic Review and Our Proposal Based on Our Experience.

Authors:  Nerina Denaro; Marco Carlo Merlano; Elvio Grazioso Russi
Journal:  Clin Exp Otorhinolaryngol       Date:  2016-06-25       Impact factor: 3.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.